Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National Medical Products Administration.

This product is indicated for short-term treatment (not exceeding 5 days) of moderate to severe acute pain in adults requiring opioid-level analgesia, and is typically used for postoperative pain relief. The product belongs to Category B of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025).

According to relevant statistics, the sales of Ketorolac Tromethamine Injection in Chinese public medical institutions in 2025 amounted to approximately RMB 230 million. The Ketorolac Tromethamine Injection of Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in November 2026, which is conducive to enriching the company's analgesic product series and enhancing the company's market competitiveness.